BioTuesdays

7.8K posts

BioTuesdays banner
BioTuesdays

BioTuesdays

@BioTuesdays

Giving great healthcare companies and their stories as much exposure as we can. Subscribe to our newsletter. https://t.co/VE9jaNcNac

Katılım Eylül 2009
392 Takip Edilen787 Takipçiler
BioTuesdays
BioTuesdays@BioTuesdays·
Medicus Pharma announced that its SKNJCT-003 Phase 2 study, evaluating the efficacy of two dose levels of D-MNA for the treatment of nodular basal cell carcinoma (BCC), has now randomized more than 50% of the 60 patients targeted for enrollment $MDCX biotuesdays.com/2025/02/14/med…
English
0
0
0
104
BioTuesdays
BioTuesdays@BioTuesdays·
Biodexa Pharmaceuticals has announced that eRapa, a form of rapamycin being developed for the treatment of familial adenomatous polyposis (FAP), has been granted Fast Track Designation by the FDA $BDRX biotuesdays.com/2025/02/10/fda…
English
0
0
1
143
BioTuesdays
BioTuesdays@BioTuesdays·
Esko Bionics names National Seating & Mobility as exclusive distributor of Ekso Indego Personal device within the complex rehabilitation technology industry $EKSO biotuesdays.com/2025/02/10/esk…
English
0
0
0
240
BioTuesdays
BioTuesdays@BioTuesdays·
New data from BioRestorative Therapies’ ongoing Phase 2 trial of cell-based BRTX-100 in cLDD potentially show disc microenvironment remodeling in addition to reported improvements in VAS and ODI $BRTX biotuesdays.com/2025/02/10/new…
English
0
2
7
333
BioTuesdays
BioTuesdays@BioTuesdays·
Tectonic Therapeutic has announced positive interim data from its Phase 1b acute hemodynamic clinical trial of TX45 in Group 2 Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction (“PH-HFpEF”) $TECX biotuesdays.com/2025/01/30/tec…
English
0
0
0
101
BioTuesdays
BioTuesdays@BioTuesdays·
Polyrizon has announced the filing of a patent application for its advanced intranasal drug delivery system Trap & Target (T&T) technology, with the Israel Patent Office (ILPO) $PLRZ biotuesdays.com/2025/01/30/pol…
English
0
0
0
147
BioTuesdays
BioTuesdays@BioTuesdays·
NLS Pharmaceutics has announced the launch of a preclinical program to evaluate Mazindol ER as a novel treatment for fentanyl dependence $NLSP biotuesdays.com/2025/01/28/nls…
English
0
0
2
329
BioTuesdays
BioTuesdays@BioTuesdays·
Conduit Pharmaceuticals has announced that the first phase in its collaboration with Sarborg, aimed at integrating advanced AI and cybernetics technology into its operations has been completed $CDT biotuesdays.com/2025/01/28/con…
English
0
1
1
558
BioTuesdays
BioTuesdays@BioTuesdays·
Stereotaxis has announced that it has received European CE Mark approval for its MAGIC ablation catheter, designed to perform cardiac ablation procedures aimed at treating heart arrhythmia $STXS biotuesdays.com/2025/01/27/ste…
English
0
0
0
170
BioTuesdays
BioTuesdays@BioTuesdays·
Veru has announced positive topline results from its Phase 2b QUALITY clinical study evaluating the safety and efficacy of enobosarm in patients receiving WEGOVY (semaglutide) for weight reduction $VERU biotuesdays.com/2025/01/27/ver…
English
0
0
0
314
BioTuesdays
BioTuesdays@BioTuesdays·
IPA (ImmunoPrecise Antibodies) has announced the development of a new class of GLP-1 therapies—leveraging AI—to enhance the efficacy, safety, and longevity of treatments for Type 2 diabetes (T2D) and obesity $IPA biotuesdays.com/2025/01/22/ipa…
English
0
0
1
133
BioTuesdays
BioTuesdays@BioTuesdays·
MeiraGTx has announced that its AAV8-RK-RetGC program for the treatment of patients with Leber congenital amaurosis due to GUCY2D mutations (LCA1) has been granted Rare Pediatric Disease Designation (RPDD) by the FDA $MGTX biotuesdays.com/2025/01/22/fda…
English
0
0
0
391